Pega to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Pegasystems Inc. (NASDAQ: PEGA), the Enterprise Transformation Company™, today announced that Ken Stillwell, COO and CFO, Pega, will be presenting at the following upcoming investor conferences:

• UBS Global Technology and AI Conference. The in-person Pega presentation is scheduled for Tuesday, December 3, 2024, at 12:15 p.m. MST (2:15 p.m. EST) in Scottsdale, AZ. Interested parties can access a live webcast of the presentation at https://event.webcasts.com/starthere.jsp?ei=1699167&tp_key=97643f59d8&tp_special=8.

• Barclays 22nd Annual Global Technology Conference. The in-person Pega presentation is scheduled for Thursday, December 12, 2024, at 8:40 a.m. PST (11:40 a.m. EST) in San Francisco, CA. Interested parties can access a live webcast of the presentation at https://event.webcasts.com/starthere.jsp?ei=1696938&tp_key=03def71f44&tp_special=8.

Archives of the presentations will be available from the Investors page of Pega’s website for a limited time.

About Pegasystems
Pega is The Enterprise Transformation Company™ that helps organizations Build for Change® with enterprise AI decisioning and workflow automation. Many of the world’s most influential businesses rely on our platform to solve their most pressing challenges, from personalizing engagement to automating service to streamlining operations. Since 1983, we’ve built our scalable and flexible architecture to help enterprises meet today’s customer demands while continuously transforming for tomorrow. For more information on how Pega empowers its clients to Build for Change®, visit www.pega.com.

All trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241126520654/en/

Press:
Lisa Pintchman
VP, Corporate Communications
[email protected]
617-866-6022
Twitter: @pega

Investor:
Peter Welburn
VP, Corporate Development & Investor Relations
[email protected]
617-498-8968

Source: Pegasystems Inc.

You May Also Be Interested In

• Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
• Vestmark Selected to Support Vanguard Custom Model Portfolios for RIAs
• Brands Likely Missing Out on Premium Traveler Spending, Finds New L.E.K. Consulting Survey